<DOC>
	<DOCNO>NCT02641067</DOCNO>
	<brief_summary>This study evaluate effect severe renal impairment pharmacokinetics doravirine .</brief_summary>
	<brief_title>A Study Evaluating Pharmacokinetics Doravirine Participants With Severe Renal Impairment ( MK-1439-051 )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Participants renal impairment : nonsmoker moderate smoker body mass index ( BMI ) ≥ 18.5 ≤ 40.0 kg/m^2 renal impairment , participant judge good health base medical history , physical examination , vital sign , laboratory safety test female informed risk pregnancy , agree become pregnant participate study . Female childbearing potential must either sexually inactive 14 day prior dose throughout study , use one acceptable birth control method female nonchildbearing potential must undergo sterilization procedure least 6 month prior dose . baseline estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m^2 Participants renal impairment : mentally legally incapacitated significant emotional problem history presence clinically significant medical psychiatric condition disease history presence alcoholism drug abuse within past 2 year history presence hypersensitivity idiosyncratic reaction study drug , inactive ingredient , related compound history presence renal artery stenosis renal transplant nephrectomy rapidly fluctuate renal function determine historical measurement female pregnant lactate positive result urine saliva drug urine breath alcohol screen screen checkin positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) unable refrain anticipates use drug , include prescription nonprescription medication , herbal remedy , vitamin supplement begin 14 day prior dose throughout study . Certain medication include treat kidney disease permit . Other medication may permit follow consultation Sponsor Clinical Monitor . unable refrain anticipates use inducer cytochrome P450 3A ( CYP3A ) permeability glycoprotein ( Pgp ) transporter least 28 day prior dose throughout study . diet incompatible onstudy diet , within 28 day prior dose , throughout study donate blood significant blood loss within 56 day prior dose donate plasma within 7 day prior dose participate another clinical trial within 28 day prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>